1. Subject has received daratumumab or other anti-CD38 therapies, within 6 months before start of treatment (however, patients treated with daratumumab monotherapy in compassionate use program or after European Medicines Agency (EMA) approval, and have progressive disease during daratumumab after previous response, or unresponsive disease to daratumumab [progressive disease after cycle 1, less than minimal response after cycle 2, or less than partial response after cycle 3], may be included in Part B)